Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jun 06, 2022
Epidiolex (Jazz Pharma) and Fintepla (Zogenix - Acquired by UCB) are locking horns in the rare developmental and epileptic encephalopathies (DEE) market with Epidiolex currently leading in terms of sale. Epidiolex has clocked over USD 650 million in sales and on the other hand Fintepla is far behind at just USD 74....
Read More...
Dec 18, 2020
The term Epilepsy isn’t new. It’s been present in the air for centuries now, however, only a few are aware that it is one of the most common neurological diseases in the world. It affects around 50 million people worldwide. However, public awareness regarding Epilepsy is quite less and it can result in the ris...
Read More...
Mar 25, 2019
What is Epilepsy? Epilepsy is a neurological disorder which mainly affects the central nervous system. It is a chronic and non-communicable disorder associated with unpredictable seizures which affect the body and can result in injuries hence is a physical condition too. Anyone can develop Epilepsy at any a...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper